日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand

在泰国，对添加SGLT2抑制剂治疗合并慢性肾病的2型糖尿病患者进行成本效益分析

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-81747-7
Chitpim, Natthakan; Leelahavarong, Pattara; Prawjaeng, Juthamas; Ittiphisit, Sakditat; Srinonprasert, Varalak; Kongmalai, Tanawan
SGLT2
糖尿病
代谢
发表日期：2025
文献求助 收藏

Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis

Onasemnogene Abeparvovec 基因疗法和 Risdiplam 用于治疗泰国脊髓性肌萎缩症：一项成本效益分析

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-024-00915-y
Khuntha, Sarayuth; Prawjaeng, Juthamas; Ponragdee, Kunnatee; Sanmaneechai, Oranee; Srinonprasert, Varalak; Leelahavarong, Pattara
神经科学
肌萎缩症
发表日期：2025
文献求助 收藏

Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis

A型肉毒杆菌毒素治疗泰国卒中后痉挛患者的成本效益和预算影响分析

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-090701
Hadnorntun, Phorntida; Prawjaeng, Juthamas; Kongmalai, Tanawan; Tanvijit, Phakamas; Chueluecha, Chuenchom; Jintakul, Nawarat; Saringcarinkul, Tipyarat; Srinonprasert, Varalak; Kumthornthip, Witsanu; Leelahavarong, Pattara
发表日期：2025
文献求助 收藏

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand

在2型糖尿病合并心力衰竭患者中，将SGLT-2抑制剂添加到标准治疗方案中的成本效益和预算影响分析：基于泰国国家数据库的洞察

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-024-00526-2
Kongmalai, Tanawan; Prawjaeng, Juthamas; Hadnorntun, Phorntida; Leelahavarong, Pattara; Chaikledkaew, Usa; Thakkinstian, Ammarin; Srinonprasert, Varalak
糖尿病
心力衰竭
心血管
代谢
发表日期：2025
文献求助 收藏

Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic

在低发病率和低死亡率环境下评估新冠疫苗的成本效益：以疫情初期泰国为例

期刊:European Journal of Health Economics
影响因子:3
doi:10.1007/s10198-022-01505-2
Wang, Yi; Luangasanatip, Nantasit; Pan-Ngum, Wirichada; Isaranuwatchai, Wanrudee; Prawjaeng, Juthamas; Saralamba, Sompob; Painter, Christopher; Briones, Jamaica Roanne; Teerawattananon, Yot
微生物学
新冠
发表日期：2023
文献求助 收藏

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

对泰国高疾病活动度类风湿关节炎患者，采用生物制剂类疾病修饰抗风湿药（bDMARDs）、靶向合成DMARDs（tsDMARDs）和生物类似药DMARDs（bsDMARDs）联合甲氨蝶呤治疗的成本效益分析

期刊:BMC Health Services Research
影响因子:
doi:10.1186/s12913-023-09595-1
Prawjaeng, Juthamas; Leelahavarong, Pattara; Budtarad, Nuttakarn; Pilasant, Songyot; Chanjam, Chonticha; Katchamart, Wanruchada; Narongroeknawin, Pongthorn; Kitumnuaypong, Tasanee
关节炎
发表日期：2023
文献求助 收藏

A Data-Driven Analysis of the Economic Cost of Non-Pharmaceutical Interventions: A Cross-Country Comparison of Kenya, Singapore, and Thailand

基于数据的非药物干预经济成本分析：肯尼亚、新加坡和泰国的跨国比较

期刊:International Journal of Public Health
影响因子:2.4
doi:10.3389/ijph.2022.1604854
Briones, Jamaica; Wang, Yi; Prawjaeng, Juthamas; Wee, Hwee Lin; Kairu, Angela; Orangi, Stacey; Barasa, Edwine; Teerawattananon, Yot
发表日期：2022
文献求助 收藏

Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines

避免未来出现问题：新冠疫苗经济评估的经验教训和建议

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-021-00661-5
Painter, Chris; Isaranuwatchai, Wanrudee; Prawjaeng, Juthamas; Wee, Hwee Lin; Chua, Brandon Wen Bing; Huynh, Vinh Anh; Lou, Jing; Goh, Fang Ting; Luangasanatip, Nantasit; Pan-Ngum, Wirichada; Yi, Wang; Clapham, Hannah; Teerawattananon, Yot
微生物学
新冠
发表日期：2021
文献求助 收藏